The content on this site is intended for healthcare professionals only
Prof Diana Lüftner speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the assessment of monoclonal antibodies from a physician's perspective.
She outlines the features that these clinical trials must include for approval - including pharmacodynamics, pharmacokinetics and response rates.
Prof Lüftner describes a particular clinical trial which aims to assess the switching process between agents.
She also explains how a physician should decide whether to use a biosimilar or the originator product.
Prof Lüftner also believes that biosimilars will become the standard of care for the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
